A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Phase 3 Completed 257 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.

Timeline

Start: 2023-02-05
Primary completion: 2024-07-01
Completion: 2024-07-01

Outcome

Met primary endpoint

registry analysis (superiority test); 10 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -16.1 (95% CI -19.9 to -12.36); Mixed Models Analysis NCT05691712 ↗

registry analysis (superiority test); 15 mg Tirzepatide vs Placebo; p <0.001; LS Mean Difference -15.9 (95% CI -19.7 to -12.10); Mixed Models Analysis NCT05691712 ↗

paper Patients receiving tirzepatide had greater reductions in HbA1c from baseline at week 40 than those receiving placebo PMID 41167231 ↗

Publications

Guo L, Dong X, Ma J, Liu M, Lu Y, Wang H, Li Q, Li L, Deng Y, Xu J. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025 Dec;13(12):1015-1029. doi: 10.1016/S2213-8587(25)00248-7. Epub 2025 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirzepatide	Peptide	5 mg	Subcutaneous
Subject	Tirzepatide	Peptide	10 mg	Subcutaneous
Subject	Tirzepatide	Peptide	15 mg	Subcutaneous